Hangzhou Biotest Biotech Co Ltd (SHG:688767) — Market Cap & Net Worth
Market Cap & Net Worth: Hangzhou Biotest Biotech Co Ltd (688767)
Hangzhou Biotest Biotech Co Ltd (SHG:688767) has a market capitalization of $889.82 Million (CN¥6.08 Billion) as of August 25, 2026. Listed on the SHG stock exchange, this China-based company holds position #9445 globally and #2358 in its home market, demonstrating a -3.44% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Hangzhou Biotest Biotech Co Ltd's stock price CN¥40.72 by its total outstanding shares 149333334 (149.33 Million). Check 688767 share price today for real-time trading data and today's change.
Hangzhou Biotest Biotech Co Ltd Market Cap History: 2021 to 2026
Hangzhou Biotest Biotech Co Ltd's market capitalization history from 2021 to 2026. Data shows change from $1.32 Billion to $889.82 Million (-9.49% CAGR).
Hangzhou Biotest Biotech Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Hangzhou Biotest Biotech Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Hangzhou Biotest Biotech Co Ltd (688767) shareholders funds to evaluate the company's book value and shareholders' equity.
Latest Price to Sales (P/S) Ratio
1.84x
Hangzhou Biotest Biotech Co Ltd's market cap is 1.84 times its annual revenue
Latest Price to Earnings (P/E) Ratio
17.64x
Hangzhou Biotest Biotech Co Ltd's market cap is 17.64 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $1.32 Billion | $1.82 Billion | $833.59 Million | 0.73x | 1.59x |
| 2022 | $911.03 Million | $1.90 Billion | $773.63 Million | 0.48x | 1.18x |
| 2023 | $641.22 Million | $442.11 Million | $106.61 Million | 1.45x | 6.01x |
| 2024 | $721.78 Million | $559.40 Million | $169.52 Million | 1.29x | 4.26x |
| 2025 | $825.57 Million | $448.37 Million | $46.80 Million | 1.84x | 17.64x |
Competitor Companies of 688767 by Market Capitalization
Companies near Hangzhou Biotest Biotech Co Ltd in the global market cap rankings as of August 25, 2026. Also see Hangzhou Biotest Biotech Co Ltd (688767) cash flow conversion for how efficiently the company converts equity into cash flow.
Key companies related to Hangzhou Biotest Biotech Co Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #188 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #323 globally with a market cap of $83.19 Billion USD.
- CSL Ltd (AU:CSL): Ranked #475 globally with a market cap of $57.77 Billion USD ( AU$81.65 Billion AUD).
- Samsung Biologics Co Ltd (KO:207940): Ranked #564 globally with a market cap of $48.66 Billion USD ( ₩71.80 Trillion KRW).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #188 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $548.05 |
| #323 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $83.19 Billion | $834.04 |
| #475 | CSL Ltd | AU:CSL | $57.77 Billion | AU$168.30 |
| #564 | Samsung Biologics Co Ltd | KO:207940 | $48.66 Billion | ₩1551000.00 |
Hangzhou Biotest Biotech Co Ltd Historical Marketcap From 2021 to 2026
Between 2021 and today, Hangzhou Biotest Biotech Co Ltd's market cap moved from $1.32 Billion to $ 889.82 Million, with a yearly change of -9.49%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥889.82 Million | +7.78% |
| 2025 | CN¥825.57 Million | +14.38% |
| 2024 | CN¥721.78 Million | +12.56% |
| 2023 | CN¥641.22 Million | -29.62% |
| 2022 | CN¥911.03 Million | -31.06% |
| 2021 | CN¥1.32 Billion | -- |
End of Day Market Cap According to Different Sources
On Aug 24th, 2026 the market cap of Hangzhou Biotest Biotech Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $889.82 Million USD |
| MoneyControl | $889.82 Million USD |
| MarketWatch | $889.82 Million USD |
| marketcap.company | $889.82 Million USD |
| Reuters | $889.82 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Hangzhou Biotest Biotech Co Ltd
Hangzhou Biotest Biotech Co.,Ltd. engages in the research and development, manufacture, sale, and service of in vitro diagnostic assays and reagents, and instruments in China and internationally. The company offers medical test products for fertility health, cardiology, oncology, inflammation, veterinary test, drug of abuse, infectious diseases, and other diagnostic rapid test. It also provides m… Read more